Ampio Pharmaceuticals Inc

ASE:AMPE   3:59:55 PM EDT
-0.08 (-3.99%)
Products, Regulatory, Earnings Announcements

Ampio Reports Positive Results For Ampion Treatment In Covid-19 Patients

Published: 09/09/2020 13:31 GMT
Ampio Pharmaceuticals Inc (AMPE) - Ampio Reports Positive Results for Ampion Treatment in Covid-19 Patients.
Ampio Pharmaceuticals Inc - Ampion Found to Be Safe and Well-tolerated With No Drug Related Adverse Events.
Ampio Pharmaceuticals Inc - Study Met Its Primary Endpoint for Safety and Tolerability of Iv Ampion Treatment.
Ampio Pharma - Ampion-treated Patients Showed Greater Improvement Versus Patients Treated With Standard of Care Including Anti-viral Therapies.
Ampio Pharmaceuticals - Believe Ampion May Be Effective in Interrupting Inflammatory Cascade Associated With Covid-19.
Ampio Pharmaceuticals Inc - Patients Will Be Followed Over Upcoming Months to Complete Safety Endpoint Assessments for Phase 1 Clinical Trial.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.02

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.02

More details on our Analysts Page.